- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05250973
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)
June 18, 2024 updated by: Janssen Research & Development, LLC
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated with D-VCd (cohort 2).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
AL amyloidosis is a rare disorder caused by clonal plasma cells that secrete immunoglobulin light chains that misfold into insoluble amyloid.
The insoluble amyloid gets deposited in vital organs which results in serious and life-threatening organ dysfunction.
Daratumumab is a human immunoglobulin (IgG1K) monoclonal antibody (mAb) that binds with high affinity to a unique epitope on cluster of differentiation 38 (CD38), a transmembrane glycoprotein.
It is a targeted immunotherapy directed towards tumor cells that overexpress CD38.
Participants will be enrolled into 2 cohorts based on cardiac involvement at baseline for cohort 1 and racial or ethnic minority with at least one organ involved for cohort 2. This study aims to generate data on risk factors for cardiac toxicity and to evaluate the cardiac safety of the proposed treatment regimens and identify potential mitigation strategies for cardiac toxicity such as deferred VCd treatment, The study will consist of screening phase (up to 28 days) and treatment phase with up to 24 treatment cycles (each cycle is 28 days).
Safety assessment will include adverse events (AEs), serious adverse events (SAEs), physical examinations, Eastern Cooperative Oncology Group (ECOG) criteria for performance status, laboratory tests and vital signs.
The overall duration of the study will be up to 3 years and 8 months.
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Recruiting
- Tom Baker Cancer Center
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Cross Cancer Institute
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- University Health Network UHN Princess Margaret Cancer Centre
-
-
-
-
-
Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Beijing, China, 100044
- Recruiting
- Peking University People s Hospital
-
Chengdu, China, 610041
- Recruiting
- West China Hospital Si Chuan University
-
Hangzhou, China, 310020
- Recruiting
- First Affiliated Hospital of Zhejiang University
-
Shanghai, China, 200025
- Recruiting
- Ruijin Hospital Shanghai Jiao Tong University
-
-
-
-
-
Limoges Cedex, France, 87042
- Completed
- CHU de LIMOGES
-
Pierre Benite cedex, France, 69495
- Recruiting
- Centre Hospitalier Lyon-Sud
-
Poitiers, France, 86000
- Recruiting
- CHU de Poitiers
-
Toulouse, France, 31400
- Recruiting
- CHU Rangueil
-
-
-
-
-
Berlin, Germany, 12203
- Recruiting
- Charite Campus Benjamin Franklin
-
Essen, Germany, 45122
- Completed
- Universitätsklinikum Essen
-
Heidelberg, Germany, 69120
- Recruiting
- Universitaetsklinikum Heidelberg Medizinische Klinik V
-
-
-
-
-
Athens, Greece, 11528
- Recruiting
- Alexandra General Hospital Of Athens
-
-
-
-
-
Napoli, Italy, 80131
- Recruiting
- Universita degli Studi di Napoli Federico II
-
Pavia, Italy, 27100
- Recruiting
- Fondazione IRCCS Policlinico San Matteo
-
Roma, Italy, 00161
- Completed
- DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA''
-
-
-
-
-
Groningen, Netherlands, 9713 GZ
- Recruiting
- University Medical Center Groningen
-
Maastricht, Netherlands, 6229 HX
- Completed
- Hospital Maastricht University Medical Center
-
Utrecht, Netherlands, 3584 CX
- Recruiting
- UMC Utrecht
-
-
-
-
-
Badalona, Spain, 08916
- Recruiting
- Hosp. Univ. Germans Trias I Pujol
-
Barcelona, Spain, 08035
- Recruiting
- Hosp. Univ. Vall D Hebron
-
Barcelona, Spain, 08036
- Recruiting
- Hosp Clinic de Barcelona
-
Madrid, Spain, 28027
- Recruiting
- Clinica Univ. de Navarra
-
Pamplona, Spain, 31008
- Recruiting
- Clinica Univ. de Navarra
-
Salamanca, Spain, 37007
- Recruiting
- Hosp Clinico Univ de Salamanca
-
-
-
-
-
Leicester, United Kingdom, LE1 5WW
- Recruiting
- Leicester Royal Infirmary - Haematology
-
London, United Kingdom, NW1 2PG
- Recruiting
- University College Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Smilow Cancer Hospital/Yale Cancer Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Recruiting
- Tufts Medical Center
-
Boston, Massachusetts, United States, 02118
- Recruiting
- Boston University Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Barbara Ann Karmanos Cancer Institute
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- Memorial Sloan Kettering
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Levine Cancer Institute
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospital of Cleveland
-
Columbus, Ohio, United States, 43214
- Recruiting
- Ohio Health Research Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- West Penn Hospital
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern Medical Center
-
-
Virginia
-
Richmond, Virginia, United States, 23219
- Recruiting
- VCU Medical Center
-
-
Washington
-
Seattle, Washington, United States, 90805
- Recruiting
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Cohort 1: Cardiac involvement (amyloid light chain [AL] amyloidosis Mayo Cardiac Stage II and Stage IIIa) with or without other organ(s) involved; Cohort 2: One or more organs impacted by systemic AL amyloidosis according to consensus guidelines
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2
- A female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
- A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 6 months after receiving the last dose of cyclophosphamide or 100 days after discontinuation of daratumumab, whichever is longer
- Cohort 2 only: self-identified racial and ethnic minorities, including Black or African American
- Measurable disease at screening defined by one of the following:
Difference between iFLC and uninvolved FLC (dFLC) >= 40mg/L per central laboratory Serum involved free light chain (iFLC) >= 40 mg/L with an abnormal kappa:lambda ratio Serum M-protein >= 0.5 g/dL
Exclusion Criteria:
- Prior therapy for systemic AL amyloidosis or multiple myeloma including medications that target cluster of differentiation 38 (CD38), with the exception of 160 milligrams(mg) dexamethasone or equivalent corticosteroid maximum exposure prior to randomization/enrollment
- Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >=60% plasma cells in the bone marrow, or hypercalcemia related to myeloma.
Participant received any of the following therapies:
- treatment with an investigational drug or used an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is less;
- vaccinated with an investigational vaccine (except for COVID-19) live, attenuated or replicating viral vector vaccines less than (<) 4 weeks prior to randomization/enrollment. Participants who are taking strong Cytochrome P450 3A4(CYP3A4) inducers must discontinue their use at least 5 half-lives prior to the first dose of bortezomib
- Stem cell transplantation -Planned stem cell transplant during the first 9 cycles of protocol therapy are excluded. Stem cell collection during the first 9 cycles of protocol therapy is permitted
- Grade 2 sensory or Grade 1 painful peripheral neuropathy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort1 (Arm A): Daratumumab + Immediate Cyclophosphamide, Bortezomib and Dexamethasone (VCd)
Participants with newly diagnosed systemic amyloid light chain (AL) amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive daratumumab 1800 milligrams (mg) subcutaneously (SC) starting on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle.
Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square [mg/m^2] either orally or intravenously [IV], bortezomib 1.3 mg/m^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
|
Daratumumab will be administered subcutaneously.
Other Names:
Cyclophosphamide will be administered either orally or IV.
Dexamethasone will be administered orally or IV.
Bortezomib will be administered by SC injection or IV.
|
Experimental: Cohort1 (Arm B): Daratumumab + Deferred VCd
Participants with newly diagnosed systemic AL amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive SC daratumumab 1800mg on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle.
Participants will also receive VCd (Cyclophosphamide 300 mg/m^2 either orally or IV, Bortezomib 1.3 mg/m^2 SC or IV, Dexamethasone 40 mg weekly either orally or IV) starting at Cycle 4 Day 1, weekly (Days 1, 8, 15, 22) in every 28-day cycle for a maximum of 6 cycles (Cycle 9 Day 22).
|
Daratumumab will be administered subcutaneously.
Other Names:
Cyclophosphamide will be administered either orally or IV.
Dexamethasone will be administered orally or IV.
Bortezomib will be administered by SC injection or IV.
|
Experimental: Cohort 2: Daratumumab + VCd
Participants with racial and ethnic minorities, including Black or African American participants, with newly diagnosed AL amyloidosis will receive SC injection of daratumumab 1800 mg SC on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle.
Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square [mg/m^2] either orally or intravenously [IV], bortezomib 1.3 mg/m^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
|
Daratumumab will be administered subcutaneously.
Other Names:
Cyclophosphamide will be administered either orally or IV.
Dexamethasone will be administered orally or IV.
Bortezomib will be administered by SC injection or IV.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Cardiac Events of Any Toxicity Grade
Time Frame: Up to 12 months
|
Number of participants with cardiac events of any toxicity grade will be reported.
|
Up to 12 months
|
Observed Concentration Immediately Prior to the Next Study Treatment Administration (Ctrough) of Daratumumab
Time Frame: Cycle 3 Day 1 predose (each cycle is of 28 days)
|
Ctrough is defined as the observed concentration immediately prior to the next study treatment administration.
|
Cycle 3 Day 1 predose (each cycle is of 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HemCR Rate
Time Frame: At 6 months
|
HemCR rate at 6 month is defined as percentage of participants who achieve HemCR at 6 month during or after the study treatment.
|
At 6 months
|
Overall Complete Hematologic Response (HemCR) Rate
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Overall HemCR rate is defined as percentage of participants who achieve HemCR during or after the study treatment.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Very Good Partial Response (VGPR) or Better Rate
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Hematologic greater than or equal to (>=) VGPR rate is defined as percentage of participants who achieve hematologic response of VGPR or better.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Time to HemCR or (VGPR or Better)
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
For participants who achieve HemCR (or >=VGPR), time to HemCR (or >=VGPR) is defined as the time between the date of first study treatment and the first efficacy evaluation at which the participant has met all criteria for hematologic complete response (CR) (or >=VGPR).
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Duration of Response (HemCR and VGPR or Better)
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
For participants who achieve HemCR (or >=VGPR), duration of HemCR (or >=VGPR) is defined as the time between the date of initial documentation of HemCR (or >=VGPR) to the date of first documented evidence of hematologic progressive disease or death, whichever comes first.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Organ Response Rate (OrRR)
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Organ response rate is defined as the percentage of participants who achieve organ response in each corresponding organ (kidney, heart, liver).
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Overall Survival (OS)
Time Frame: Until Cycle 12 or Month 12 (whichever occurs later)
|
OS is measured from the date of first study treatment to the date of the participant's death.
|
Until Cycle 12 or Month 12 (whichever occurs later)
|
Time to Subsequent Therapy
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Time to subsequent therapy for amyloid light chain (AL) amyloidosis is defined as the time from the date of first study treatment to the start date of subsequent AL amyloidosis (non-protocol) treatment.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Number of Participants with Adverse Events (AEs) by Severity
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Number of participants with AEs by severity will be reported.
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Serum Concentration of Daratumumab
Time Frame: Up to 3 years
|
Serum samples will be analyzed to determine concentrations of daratumumab.
|
Up to 3 years
|
Number of Participants with Antibodies to Daratumumab
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Number of participants with antibodies to daratumumab will be reported.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Number of Participants with Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Number of participants with antibodies to rHuPH20 will be reported.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Change from Baseline in Clinical Signs and Symptoms Score of Cardiac AL Amyloidosis
Time Frame: Up to Cycle 12 or Month 12 (whichever occurs later)
|
Change from baseline in clinical signs and symptoms score of cardiac AL amyloidosis will be reported.
|
Up to Cycle 12 or Month 12 (whichever occurs later)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2022
Primary Completion (Estimated)
November 29, 2024
Study Completion (Estimated)
December 31, 2027
Study Registration Dates
First Submitted
February 11, 2022
First Submitted That Met QC Criteria
February 11, 2022
First Posted (Actual)
February 22, 2022
Study Record Updates
Last Update Posted (Actual)
June 20, 2024
Last Update Submitted That Met QC Criteria
June 18, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Proteostasis Deficiencies
- Amyloidosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dexamethasone
- Cyclophosphamide
- Daratumumab
- Bortezomib
Other Study ID Numbers
- CR109160
- 2021-002639-48 (EudraCT Number)
- 54767414AMY2009 (Other Identifier: Janssen Research & Development, LLC)
- 2023-507069-25-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyloidosis
-
Millennium Pharmaceuticals, Inc.CompletedLight-Chain AmyloidosisUnited States, Canada, France, Germany, Italy
-
Boston UniversityCorino Therapeutics, Inc.CompletedTransthyretin Amyloidosis | Amyloidosis, Leptomeningeal, Transthyretin-RelatedUnited States
-
Chulalongkorn UniversityUnknown
-
Criterium, Inc.AmgenCompletedAmyloidosis | Systemic Light Chain AmyloidosisUnited States
-
Steen Hvitfeldt PoulsenRecruitingTransthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Wild-Type Transthyretin-Related (ATTR)AmyloidosisDenmark
-
IRCCS Policlinico S. MatteoRecruiting
-
University Hospital Center of MartiniqueTerminated
-
Peking Union Medical College HospitalActive, not recruitingLight Chain (AL) Amyloidosis | Venetoclax | CCND1 TranslocationChina
-
Kaneka Medical America LLCRecruitingDialysis AmyloidosisUnited States
-
Peking Union Medical College HospitalXian-Janssen Pharmaceutical Ltd.Active, not recruitingAmyloidosis; SystemicChina
Clinical Trials on Daratumumab
-
Janssen Research & Development, LLCActive, not recruitingSmoldering Multiple MyelomaUnited States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
-
Boston Medical CenterJanssen PharmaceuticalsCompleted
-
National Cancer Institute (NCI)RecruitingLymphoma, Primary EffusionUnited States
-
Ostfold Hospital TrustOdense University Hospital; Oslo University Hospital; Haukeland University Hospital and other collaboratorsActive, not recruiting
-
Ronald WittelesCompletedHeart Transplant Failure and Rejection | AllosensitizationUnited States
-
University of ArkansasJanssen Scientific Affairs, LLCRecruiting
-
Incyte CorporationTerminatedRelapsed or Refractory Multiple MyelomaUnited States, Spain, Germany
-
Marc L Gordon, MDJanssen Scientific Affairs, LLCCompletedAlzheimer DiseaseUnited States
-
Hoffmann-La RocheCompletedMultiple MyelomaUnited States, Australia, United Kingdom
-
Charite University, Berlin, GermanyJanssen-Cilag G.m.b.H; Labor Berlin-Charité Vivantes G.m.b.H; Deutsches Rheuma-Forschungszentrum... and other collaboratorsNot yet recruiting